blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1497287

EP1497287 - Quinoline derivatives in combination with 5-FU or CPT-11 for use in the treatment of cancer [Right-click to bookmark this link]
Former [2005/03]QUINOLINONE DERIVATIVES
[2010/14]
StatusNo opposition filed within time limit
Status updated on  30.09.2011
Database last updated on 08.06.2024
Most recent event   Tooltip04.10.2013Lapse of the patent in a contracting state
New state(s): HU		published on 06.11.2013  [2013/45]
Applicant(s)For all designated states
Novartis Vaccines and Diagnostics, Inc.
4560 Horton Street
Emeryville, CA 94608 / US
[2007/04]
Former [2005/03]For all designated states
CHIRON CORPORATION
4560 Horton Street
Emeryville California 94608-2916 / US
Inventor(s)01 / RENHOWE, Paul A.
262 Stetson Drive
Danville, CA 94506 / US
02 / PECCHI, Sabina
5834 Merriewood Drive
Oakland, CA 94506 / US
03 / MACHAJEWSKI, Timothy D.
2514 Norwalk Court
Martinez, CA 94553 / US
04 / SHAFER, Cynthia M.
4868 El Grande Place
El Sobrante, CA 94803 / US
05 / TAYLOR, Clarke
612 Adams Street
Albany, CA 94706 / US
06 / McCREA, William R.
1040 Amito Drive
Berkeley, CA 94705 / US
07 / McBRIDE, Christopher
4504 Lawton Avenue
Oakland, CA 94609 / US
08 / JAZAN, Elisa
520 McLaughlin Avenue
Richmond, CA 94805 / US
09 / HEISE, Carla
436 Hawthorne Lane
Benicia, CA 94510 / US
 [2005/03]
Representative(s)Marshall, Cameron John, et al
Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
[N/P]
Former [2005/03]Marshall, Cameron John, et al
Carpmaels & Ransford 43-45 Bloomsbury Square
London WC1A 2RA / GB
Application number, filing date03746614.104.04.2003
[2005/03]
WO2003US10463
Priority number, dateUS2002011611705.04.2002         Original published format: US 116117
[2005/03]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO03087095
Date:23.10.2003
Language:EN
[2003/43]
Type: A1 Application with search report 
No.:EP1497287
Date:19.01.2005
Language:EN
The application published by WIPO in one of the EPO official languages on 23.10.2003 takes the place of the publication of the European patent application.
[2005/03]
Type: B1 Patent specification 
No.:EP1497287
Date:24.11.2010
Language:EN
[2010/47]
Search report(s)International search report - published on:US23.10.2003
(Supplementary) European search report - dispatched on:EP08.06.2007
ClassificationIPC:A61K31/47, A61K31/4166, A61K31/4745, A61K45/06, A61P35/00
[2007/28]
CPC:
C07D471/04 (EP,US); A61K31/4704 (KR); A61K31/19 (EP,US);
A61K31/439 (EP,US); A61K31/47 (EP,US); A61K31/4709 (EP,US);
A61K31/4745 (EP,US); A61K31/496 (EP,US); A61K31/513 (EP,US);
A61K31/5377 (EP,US); A61K31/541 (EP,US); A61P35/00 (EP);
A61P35/04 (EP); A61P43/00 (EP); A61P9/00 (EP);
C07D401/04 (EP,US); C07D401/14 (EP,US); C07D405/04 (EP,US);
C07D409/04 (EP,US); C07D413/04 (EP,US); C07D417/04 (EP,US);
C07D417/14 (KR); C07D453/02 (EP,US) (-)
C-Set:
A61K31/19, A61K2300/00 (EP,US);
A61K31/4745, A61K2300/00 (US,EP);
A61K31/513, A61K2300/00 (US,EP)
Former IPC [2005/03]C07D417/14
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   RO,   SE,   SI,   SK,   TR [2005/03]
Extension statesALNot yet paid
LTNot yet paid
LVNot yet paid
MKNot yet paid
TitleGerman:Chinolinonderivate in Kombination mit 5-FU oder CPT-11 für die Verwendung in der Behandlung von Krebs[2010/14]
English:Quinoline derivatives in combination with 5-FU or CPT-11 for use in the treatment of cancer[2010/14]
French:Dérivés de quinoline en combinaison avec 5-FU ou CPT-11 pour leur utilisation dans le traitement du cancer[2010/14]
Former [2005/03]CHINOLINONDERIVATE
Former [2005/03]QUINOLINONE DERIVATIVES
Former [2005/03]DERIVES DE QUINOLINONE
Entry into regional phase02.11.2004National basic fee paid 
02.11.2004Search fee paid 
02.11.2004Designation fee(s) paid 
02.11.2004Examination fee paid 
Examination procedure23.09.2003Request for preliminary examination filed
International Preliminary Examining Authority: US
02.11.2004Examination requested  [2005/03]
07.01.2005Amendment by applicant (claims and/or description)
06.11.2007Despatch of a communication from the examining division (Time limit: M06)
16.05.2008Reply to a communication from the examining division
11.12.2008Despatch of a communication from the examining division (Time limit: M06)
22.06.2009Reply to a communication from the examining division
01.07.2009Despatch of a communication from the examining division (Time limit: M02)
11.09.2009Reply to a communication from the examining division
01.04.2010Communication of intention to grant the patent
10.08.2010Fee for grant paid
10.08.2010Fee for publishing/printing paid
Opposition(s)25.08.2011No opposition filed within time limit [2011/44]
Fees paidRenewal fee
02.11.2004Renewal fee patent year 03
27.03.2006Renewal fee patent year 04
10.04.2007Renewal fee patent year 05
28.03.2008Renewal fee patent year 06
16.04.2009Renewal fee patent year 07
25.03.2010Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCY24.11.2010
CZ24.11.2010
DK24.11.2010
EE24.11.2010
FI24.11.2010
HU24.11.2010
RO24.11.2010
SE24.11.2010
SI24.11.2010
SK24.11.2010
BG24.02.2011
IE04.04.2011
LU04.04.2011
MC30.04.2011
[2013/45]
Former [2013/25]CY24.11.2010
CZ24.11.2010
DK24.11.2010
EE24.11.2010
FI24.11.2010
RO24.11.2010
SE24.11.2010
SI24.11.2010
SK24.11.2010
BG24.02.2011
IE04.04.2011
LU04.04.2011
MC30.04.2011
Former [2012/20]CY24.11.2010
CZ24.11.2010
DK24.11.2010
EE24.11.2010
FI24.11.2010
RO24.11.2010
SE24.11.2010
SI24.11.2010
SK24.11.2010
BG24.02.2011
IE04.04.2011
MC30.04.2011
Former [2012/01]CY24.11.2010
CZ24.11.2010
DK24.11.2010
EE24.11.2010
FI24.11.2010
RO24.11.2010
SE24.11.2010
SI24.11.2010
SK24.11.2010
BG24.02.2011
MC30.04.2011
Former [2011/38]CY24.11.2010
CZ24.11.2010
DK24.11.2010
EE24.11.2010
FI24.11.2010
RO24.11.2010
SE24.11.2010
SI24.11.2010
SK24.11.2010
BG24.02.2011
Former [2011/31]CY24.11.2010
FI24.11.2010
SE24.11.2010
SI24.11.2010
BG24.02.2011
Former [2011/24]CY24.11.2010
FI24.11.2010
SE24.11.2010
Documents cited:Search[Y]WO0071129  (BRISTOL MYERS SQUIBB CO [US]) [Y] 1-17* page 12 *;
 [Y]WO0222598  (CHIRON CORP [US], et al) [Y] 1-17 * page 5 - page 11 * * page 95 * * page 106 - page 149 *
International search[X]WO0128993  (MERCK & CO INC [US], et al);
 [XP]US2002103230  (RENHOWE PAUL A [US], et al);
 [XP]US2002107392  (RENHOWE PAUL A [US], et al);
 [XP]US2003028018  (RENHOWE PAUL A [US], et al)
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.